Table 3. TGF-β1 genotype and brain metastasis-free survival in 102 NSCLC patients without distant metastasis and 39 NSCLC patients with brain metastasis.

Polymorphism and Genotypes	Univariate Analysis			Multivariate Analysis
	HR*	95%CI	P	HR*	95%CI	P
rs1800469 (C–509T)
CC (n = 125)	1.000			1.000
CT+TT (n = 80)	1.901	1.901–3.581	0.047	1.624	0.802–3.286	0.178
rs1800471 (G915C)
GG (n = 178)	1.000			1.000
CG+CC (n = 27)	1.341	0.592–3.038	0.371	1.380	0.534–3.566	0.506
rs1982073 (T+29C)
TT (n = 68)	1.000			1.000
CT+CC (n = 137)	2.339	1.1109–4.936	0.026	2.567	1.155–5.702	0.021

^*Compared with 102 patients without distant metastasis.

NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval. HRs were estimated from Cox proportional hazard models and adjusted for age, sex, race, Karnofsky performance score, smoking status, histology, disease stage, gross tumor volume, concurrent chemotherapy, number of cycles of chemotherapy, and radiation dose received.